Endocyte, Inc.  

(Public, NASDAQ:ECYT)   Watch this stock  
Find more results for ECYT
4.75
-0.19 (-3.85%)
After Hours: 4.72 -0.03 (-0.63%)
Dec 11, 7:06PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.70 - 5.06
52 week 1.17 - 6.55
Open 4.97
Vol / Avg. 382,067.00/700,473.00
Mkt cap 202.23M
P/E     -
Div/yield     -
EPS -1.35
Shares 42.38M
Beta 2.20
Inst. own 37%
Nov 15, 2017
Endocyte Inc at Jefferies Global Healthcare Conference
Nov 6, 2017
Q3 2017 Endocyte Inc Earnings Call - Webcast
Oct 2, 2017
Endocyte, Inc. - Special Call - Webcast
Sep 26, 2017
Endocyte Inc at Cantor Fitzgerald Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -71590.22% -62696.53%
Operating margin -72496.89% -63886.17%
EBITD margin - -62572.16%
Return on average assets -81.58% -27.27%
Return on average equity -85.74% -28.45%
Employees 76 -
CDP Score - -

Address

3000 Kent Ave Ste A1-100
WEST LAFAYETTE, IN 47906
United States - Map
+1-765-4637175 (Phone)
+1-765-4639271 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Officers and directors

John C. Aplin Ph.D. Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Michael A. Sherman President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Michael T. Andriole Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Philip S. Low Ph.D. Chief Science Officer, Director
Age: 67
Bio & Compensation  - Reuters
Michael A. Brinkley Vice President - Quality
Age: 51
Bio & Compensation  - Reuters
Christopher P. Leamon Ph.D. Vice President - Research
Age: 49
Bio & Compensation  - Reuters
P. David Mozley M.D. Vice President - Imaging
Bio & Compensation  - Reuters
Katherine K. Parker Vice President of Human Resources
Age: 50
Bio & Compensation  - Reuters
Beth A. Taylor Corporate Controller
Age: 49
Bio & Compensation  - Reuters
Cooper Lesley Russell Director
Age: 56
Bio & Compensation  - Reuters